The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Pisa Syndrome in a Patient in a Wheelchair Taking Valproic Acid

To the Editor:

Pisa syndrome (pleurothotonus) is a condition characterized by sustained flexion of the body with the head to one side, creating a “Leaning Tower” posture. It was first described by Ekbom et al. in 1972 (1). General incidence rates are not well established, although it appears to be more common in older patients; an 8% incidence was found in one series of newly admitted geropsychiatric patients (2). Most authors have described Pisa syndrome as a side effect of prolonged exposure to conventional neuroleptics (3). More recently, other agents, including atypical antipsychotics, cholinesterase inhibitors, antiemetics, and tricyclic antidepressants, have been implicated (4). Although treatment with anticholinergic agents has been proposed, definitive therapy remains the discontinuation of the offending agent (5). We report a case of suspected Pisa syndrome in a 65-year-old patient in a wheelchair receiving valproic acid.

Mr. A was a 65-year-old nursing home resident being treated for schizoaffective disorder. He was in a wheelchair secondary to severe arthritis. His medications were 750 mg b.i.d. of valproic acid, 200 mg b.i.d. of carbamazepine, and 3 mg b.i.d. of risperidone—a regimen that had been stable and unchanged over several months. His valproic acid and carbamazepine levels were monitored routinely and were never above the therapeutic range.

Over a few weeks, the staff noticed that Mr. A had begun leaning to one side, a change that progressed to the point at which he was tilted at a 30° angle throughout the day. He seemed unaware of and unconcerned by this change. He showed no other signs or symptoms suggestive of an extrapyramidal syndrome. The only medication change to which Mr. A consented was a trial discontinuation of valproic acid. Immediately upon discontinuation, his posture returned to a stable, upright position.

Pisa syndrome has not been reported in association with valproic acid, but our patient’s dramatic improvement with its discontinuation strongly suggests a medication-related effect, either solely due to valproic acid or perhaps secondary to a pharmacodynamic interaction between valproic acid and risperidone. We believe that this patient’s wheelchair state contributed to a delay in recognizing this condition and hope this report will heighten awareness to the fact that this syndrome can occur in nonambulatory patients.

References

1. Ekbom K, Lindholm H, Ljungberg L: New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972; 202:94–103MedlineGoogle Scholar

2. Yassa R, Nastase C, Cvejic J, Laberge G: The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry 1991; 29:942–945Crossref, MedlineGoogle Scholar

3. Duggal HS, Sivamony S, Umapathy C: Pisa syndrome and atypical antipsychotics (letter). Am J Psychiatry 2004; 161:373LinkGoogle Scholar

4. Villarejo A, Camacho A, Garcia-Ramos R, Moreno T, Penas M, Juntas R, Ruiz J: Cholinergic-dopaminergic imbalance in Pisa syndrome. Clin Neuropharmacol 2003; 26:119–121Crossref, MedlineGoogle Scholar

5. Bhattacharya KF, Giannakikou I, Munroe N, Chaudhuri KR: Primary anticholinergic-responsive Pisa syndrome. Mov Disord 2000; 15:1285–1287Crossref, MedlineGoogle Scholar